



1/16

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NUMBER CMT-0069 SERIAL NUMBER 10/584,983 FILED 6/30/2006
FIRST INVENTOR: Taehwan KWAK TITLE OBESITY AND METABOLIC SYNDROME
TREATMENT WITH TANSHINONE DERIVATIVES WHICH INCREASE METABOLIC
ACTIVITY EXAMINER NYA ART UNIT NYA

- Applicant submits herewith a copy of (a) attached form PTO-1449, which lists all patents, publications, applications, or other information submitted for consideration by the Office; (b) a legible copy of each document required by 37 C.F.R. §1.98(b)(2).
- Applicant herein apprises the Patent Office of references cited in a parent U.S. application from which this application obtains the benefit of an earlier filing date under 35 U.S.C. §120. The Serial Number of the parent application is U.S. Application _____ filed _____ and entitled _____. The publications cited therein are listed on attached Form PTO-1449. In accordance with 37 C.F.R. §1.98(d) copies of the listed publications are not required. Additional parent patent applications are listed on an attached sheet.
- In accordance with 37 C.F.R. §1.98(a)(3), Applicant hereby certifies that for each reference not in English (check at least one box below):
 A copy of a translation of one or more non-English document, or portion thereof, is provided herewith;
 A concise explanation is (check at least one box below):
 provided in the accompanying foreign or international search report; incorporated into the specification; and/or provided herewith.

37 C.F.R. §1.97(b)(1), (b)(2) – WITHIN 3 MONTHS OF FILING OR ENTRY IN NATIONAL STAGE

- Since this Information Disclosure Statement is being filed within three months of the filing date of the subject application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application, no fee or certification under 37 C.F.R. §1.97(e) is required.

37 C.F.R. §1.97(b)(3), (b)(4) – PRIOR TO MAILING OF FIRST OFFICE ACTION OR FIRST ACTION AFTER REQUEST FOR CONTINUED EXAMINATION

- Since this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114, no fee or certification under 37 C.F.R. §1.97(e) is required.

37 C.F.R. §1.97(c) – AFTER FIRST ACTION, BEFORE FINAL ACTION OR ALLOWANCE

- Since this Information Disclosure Statement is being filed outside of the period provided for in 37 C.F.R. §1.97(b), but before the mailing date of a Final Rejection or Notice of Allowance, this submission is being accompanied by (one of the following boxes must be checked):
 - the fee required under 37 C.F.R. §1.97(c)(2) and specified in 37 C.F.R. §1.17(p).
 - the statement specified in 37 C.F.R. §1.97(e) (Box 8 or 9 must be checked).

37 C.F.R. §1.97(d) – AFTER FINAL REJECTION OR ALLOWANCE

- Since this Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(c), but on or before payment of the issue fee and is accompanied by both the statement specified in 37 C.F.R. §1.97(e) and the fee set forth in 37 C.F.R. §1.17(p). (Box 8 or 9 must be checked.)
- In accordance with 37 C.F.R. §1.97(e)(1), Applicant's attorney certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. The foreign or international search report(s) is/are enclosed.
- In accordance with 37 C.F.R. §1.97(e)(2), Applicant's attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of the information disclosure statement.
- In the event the Commissioner of Patents deems that any additional fee is required under 37 C.F.R. §§ 1.16 or 1.17 in connection with this application, Applicant's attorneys authorize that such fee be charged to Deposit Account No. 06-1130.

11. Consideration of this Information Disclosure Statement is respectfully requested.


Name:	<u>Amy Bizon-Copp</u>	Registration Number	<u>53,993</u>
Signature	<u>Amy Bizon-Copp</u>	Date	<u>11-13-2006</u>

CERTIFICATE OF MAILING OR TRANSMISSION: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or [] facsimile transmitted to the U.S. Patent and Trademark Office to Facsimile No. _____ on the date shown below.

Name	<u>Desiree Bobo</u>	Date	<u>11-13-2006</u>
Signature	<u>Desiree Bobo</u>	Date	<u>11-13-2006</u>



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)



ATTY DOCKET NO. CMT-0069	APPLICATION NO. 10/584,983
APPLICANT(S) Taehwan KWAK, et al.	
FILING DATE 6-30-2006	GROUP ART UNIT NYA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	20030114431	6-19-2003	GIROUARD	514	182	8-26-2002

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	1020010019147	3-15-2001	KOREA w/English Abstract				
	1020040084482	10-6-2004	KOREA w/English Abstract				
	1020000027306	5-15-2000	KOREA w/English Abstract				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Stimulation of AMP-Activated Protein Kinase (AMPK) Is Associated with Enhancement of Glut 1-Mediated Glucose Transport; Author: Abbud, et al.; Arch. Biochem. Biophys.; vol. 380, pp. 347-352, 2000
	Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase; Author: Zheng, et al.; J. Appl. Physiol.; vol. 91, pp. 1073-1083, 2001

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
CMT-0069

APPLICATION NO.
10/584,983

Taeewan KWAK, et al.

FILING

6-30-2006

GROUP ART

NYA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
z A							

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
z							
A							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Coordinate Regulation of Malonyl-CoA Decarboxylase, sn-Glycerol-3-phosphate Acyltransferase, and Acetyl-CoA Carboxylase by AMP-activated Protein Kinase in Rat Tissues in Response to Exercise; Author: Park, et al.; J. Biol. Chem.; vol. 277, pp. 32571-32577, 2002

Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle; Author: Park, et al.; J. Appl. Physiol.; vol. 92, pp. 2475-2482, 2002

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
CMT-0069

APPLICATION NO.
10/584,983

Taehwan KWAK, et al.

FILING GROUP ART
6-30-2006 NYA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Mechanism for Fatty Acid "Sparing" Effect on Glucose-induced Transcription; Author: Kawaguchi, et al.; J. Biol. Chem.; vol. 277, pp.3829-3835,2002

Inhibition of Inducible Nitric-oxide Synthase by Activators of AMP-activated Protein Kinase; Author: Pilon, et al.; J. Biol. Chem.; vol. 279,pp. 20767-74, 2004

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

 ATTY DOCKET NO.
CMT-0069

 APPLICATION NO.
10/584,983
Taehwan KWAK, et al.
FILING
6-30-2006
GROUP ART
NYA
U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AMP Kinase and Malonyl-COA: Targets for Therapy of the Metaolic Syndrome; Author: Ruderman, et al.; Nature drug discovery; vol. 3,pp. 340-351, April 2004

PPARy coactivator-1a expression during thyroid hormone-and contractile activity-induced mitochondrial adaptations; Author: Irrcher, et al.; Am. J. Physiol. Cell Physiol.; vol. 284, c1669-c1677, 2003

EXAMINER
DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
CMT-0069

APPLICATION NO.
10/584,983

Taehwan KWAK, et al.

FILING

6-30-2006

GROUP ART

NYA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AMP-activated protein kinase phosphorylation of endothelial NO synthase; Author: Chen, et al.; FEBS Letters 443,pp. 285-289, 1999

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 AND NRF1, Author: Patti, et al.; PNAS ;vol. 100, No. 14; pp. 8466-8471, 2003

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) CMT-0069	Application Number 10/584,983
Applicant(s) Taehwan KWAK, et al.	
Filing Date 6-30-2006	Group Art Unit NYA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*EXAMINER INITIAL	Inhibitory Activity of Diacylglycerol Acyltransferase by Tanshinones from the Root <i>Salvia miltiorrhiza</i> ; Author: Ko, et al.; Arch. Pharm. Res.; vol. 25, pp. 446-448, 2002
	Dihydrosotanshinone I Protects Against Menadione-Induced Toxicity in a Primary Culture of Rat Hepatocytes; Author: Ip, et al.; <i>Planta Med.</i> ; 68, pp. 1077-1081, 2002
	Aldose Reductase Inhibitory Constituents of the Root of <i>Salvia miltiorrhiza</i> BUNGE; Author: Tezuka, et al.; <i>Chem. Pharm. Bull.</i> ; vol. 45, No. 8; pp. 1306-1311, 1997
	Possible Active Components of Tan-Shen (<i>Salvia miltiorrhiza</i>) for Protection of the Myocardium Against Ischemia-Induced Derangements; Author: Yagi, et al.; <i>Planta Med.</i> ; vol. 55; pp. 51-54, 1989
	Role of UCP2 and UCP3 in Nutrition and Obesity; Author: Nagy, et al.; <i>Nutrition</i> ; vol. 20, pp. 139-144, 2004
	Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia; Author: Marsin, et al.; <i>Curr. Biol.</i> ; vol. 10, pp. 1247-1255, 2000
	5-Aminoimidazole-4-Carboxamide Riboside Mimics the Effects of Insulin on the Expression of the 2 Key Gluconeogenic Genes PEPCK and Glucose-6-Phosphatase; Author: Lochead, et al.; <i>Diabetes</i> ; vol. 49, pp. 896-903, 2000
	Mitochondrial fission in apoptosis, neurodegeneration and aging; Author: Bossy-Wetzel, et al.; <i>Curr. Opin. Cell Biol.</i> ; vol. 15, pp. 706-716, 2003
	Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance; Author: Peterson, et al.; <i>Science</i> ; vol. 300, pp. 1140-1142, 2003
	Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus; Author: LEE, et al.; <i>Diabetes Res. Clin. Pract.</i> ; vol. 42, pp. 161-167, 1998
	Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1; Author: WU, et al.; <i>Cell</i> ; vol. 98, pp. 115-124, 1999
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional) CMT-0069	Application Number 10/584,983
Applicant(s) Taehwan KWAK, et al.	
Filing Date 6-30-2006	Group Art Unit NYA

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Effects of Tanshinone VI on the Hypertrophy of Cardiac Myocytes and Fibrosis of Cardiac Fibroblasts fo Neonatal Rats; Author: Maki, et al.; Planta Med.; vol. 68, pp. 1103-1107,2002
	Tanshinones inhibit mast cell degranulation by interfering with IgE receptor-mediated tyrosine phosphorylation of PLCgamma2 and MAPK; Author: Choi, et al.; Planta Med.; vol. 70,pp. 178-180, 2004
	Novel Diterpenoid acetylcholinesterase Inhibitors from Salvia miltiorrhiza; Author: Ren, et al.; Planta Med.;vol. 70, pp. 201-204 , 2004
	Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells; Author: Takahashi, et al.; Biochemical Pharmacology; vol. 64, pp. 745-750,2002
	Antibacterial Activities of Cryptotanshinonee and Dihydrotanshinone I from a Medicinal Herb, Salvia miltiorrhiza Bunge; Author: Lee, et al.; Biosci. Biotechnol. Biochem.; vol. 63(12), pp. 2236-2239,1999
	Inhibition of interleukin-12 and interferon- γ production in immune cells by tanshinones from Salvia miltiorrhiza; Author: Kang, et al.; Immunopharmacology; vol. 49, pp. 355-361,2000
	Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria; Author: Zhou, et al.; Biochemical Pharmacology; vol. 65, pp. 51-57, 2003
	Tanshinone (Salvia miltiorrhzae Extract) Preparations Attenuate Aminoglycoside-Induced Free Radical Formation In Vitro and Ototoxicity In Vivo; Author; Wang, et al.; Antimicrobial Agent & Chemotherapy; vol. 47, No. 6; pp. 1836-1841, June 2003
	INTERNATIONAL SEARCH REPORT ; International Application No. PCT/KR2004/003546; International Filing date: December 30, 2004; Date of Mailing March 11, 2005 (All references cited in Search Report are listed above)
	Written Opinion for Application No. PCT/KR2004/003546 dated December 30, 2004
	International Preliminary Exam Report for Application No. PCT/KR2004/003546 dated December 30, 2004
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.